Background: Accurate preoperative risk stratification of intraductal papillary mucinous neoplasms (IPMNs) remains a major challenge in pancreatic surgery. Cytology obtained through endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) demonstrates high specificity but limited sensitivity, whereas molecular analysis of cyst fluid—particularly KRAS and GNAS mutations—has emerged as a promising complementary diagnostic tool. Methods: We conducted a narrative review combined with a retrospective single-center observational study of patients evaluated for suspected IPMN between 2018 and 2025 who underwent EUS-FNA with cytology and KRAS/GNAS testing followed by surgical resection. Histology was used as the reference standard. Given the limited number of resected cases (n = 25), results should be interpreted with caution. Results: A total of 105 patients were included, of whom 70 underwent EUS-FNA and 25 surgical resection. Final histology showed low-grade dysplasia in 12 cases (48%) and high-grade dysplasia in 13 cases (52%), with no invasive carcinoma detected, limiting the evaluation of diagnostic performance for invasive disease. Cytology demonstrated a sensitivity of 38.5% and specificity of 75% for advanced neoplasia. Molecular testing achieved 100% sensitivity but low specificity. A combined diagnostic strategy increased sensitivity to 92.3% compared with 38.5% for cytology alone, although with reduced specificity. Conclusions: A multimodal diagnostic approach integrating morphology, cytology, and molecular testing improves risk stratification of IPMNs and may supports surgical decision-making within multidisciplinary pancreatic teams, particularly in indeterminate cases, although its impact should be interpreted in the context of limited sample size.
Mastrangelo et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: